
ASRT Stock Forecast & Price Target
ASRT Analyst Ratings
Bulls say
Assertio Hldgs is currently undervalued, with a calculated firm value of approximately $260M and a price objective of $35.00 per share. The company's diversified product portfolio, strong cash position, and potential for international growth present significant investment opportunities. However, risks such as market competition and a potential equity dilution should be considered before making any investment decisions.
Bears say
Assertio Hldgs is being acquired by Garda Therapeutics and all non-Rolvedon assets are being sold to Cosette Pharmaceuticals. This acquisition represents a premium to Assertio's unaffected stock price, but also reflects a potential lack of future growth potential for the company's products and pipeline. Additionally, the inclusion of a non-tradeable CVR further reflects the uncertainty around Assertio's future performance.
This aggregate rating is based on analysts' research of Assertio Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ASRT Analyst Forecast & Price Prediction
Start investing in ASRT
Order type
Buy in
Order amount
Est. shares
0 shares